“PVPs are one of the most widely used excipients in pharmaceuticals,” Matthew Dickman, International Business Director at Azelis, told in-Pharmatechnologist.com, and this deal will see the Belgian chemicals distributor supply ingredients manufactured by Chinese firm JHNH at its facility in Quzhou to customers in Europe, Russia, Turkey and North Africa.
“The product is very widely used in combination with a significant number of active pharmaceutical ingredients (APIs),” he continued, adding “there is significant demand across a wide number of customers.”
These excipients are readily soluble in water, essentially chemically inert, physiologically compatible, non-toxic, temperature-resistant, non-ionic and colourless and, are therefore ideally suited for use in medicines and pharmaceutical applications, Dickman said.
PVP is thus used as a tablet binder, drug solubiliser for injectables, medical lubricant, and also in patches. “Many of the most significant formulators will use this product so the target market is large.”
The collaboration will see Azelis enabling “customers to have access to JHNH products in Europe and vice versa via a safe, compliant and secure route to market,” Dickman told us.
“They are a leading manufacturer of PVP and meet all international standards for quality and safety,” he continued, whilst “Azelis runs six sites across Europe that run a qualification procedure for every distributed substance. We have a good fit.”
Having already established a history in sourcing and supply of APIs from China, Dickman said the firm is “experienced in transparency, correct documentation and supply chain and safety issues.
“Much of what we do for APIs also applies to excipients as many customers who buy APIs from us also buy excipients.”
He added: “We take extra precautions to ensure that the customers who need to qualify every ingredient used in their manufacturing can be sure that Azelis will give them every possible support to enable secure and safe compliance.”